drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (gene-engineered TCR-T)
drug_description
Autologous gene-engineered TCR-T cell therapy expressing an HLA-A*0201–restricted TCR specific for the H3.3K27M neoantigen; endogenous TCR is inhibited to reduce mispairing and off-target reactivity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express an HLA-A*0201–restricted T-cell receptor specific for the H3.3K27M neoantigen on glioma cells. Upon recognition of the H3.3K27M peptide presented on MHC class I, the T cells activate and kill target cells via perforin/granzyme cytotoxicity and cytokine release. The endogenous TCR is inhibited to reduce mispairing and off-target reactivity; therapy relies on HLA-A*0201 restriction.
drug_name
Autologous anti-H3.3K27M TCR-expressing T cells (KIND T cells)
nct_id_drug_ref
NCT05478837